NASDAQ$CARM
Carisma Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Carisma Therapeutics reported financial results for the third quarter of 2023 and highlighted recent business updates.
Carisma Therapeutics reported its Q3 2023 financial results, highlighting advancements in clinical and pre-clinical programs, including data from the Phase 1 clinical study of CT-0508 and pre-clinical work with Moderna. The company's cash, cash equivalents, and marketable securities are expected to fund operations into the first quarter of 2025.
- Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit.
- Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte.
- Presented pre-clinical proof of concept data of in vivo CAR-M from the collaboration with Moderna at SITC.
- Cash, cash equivalents and marketable securities of $94.1 million are expected to fund the company into the first quarter of 2025.
Headline financials
Revenue & EPS history
Carisma Therapeutics · Revenue · Quarterly
$3.83M
Revenue by segment
Carisma Therapeutics · $19.6M total across 1 segment · Q4 2024
- Collaboration Revenues$19.6M—100.0%
Forward guidance
Carisma Therapeutics believes its current cash, cash equivalents, and marketable securities will sustain planned operations into the first quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2023
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+6.2%
Avg return
30 days after
54%
26 / 48 earnings
Positive
+32.8%
Q2 2016
Best reaction
-29.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +6.2% | +10.1% | -98.0% | |
| Q3 2025 | +2.4% | +27.8% | +22.6% | |
| Q2 2025 | -11.8% | -8.6% | +31.7% | |
| Q1 2025 | +3.1% | -1.4% | +153.1% | |
| Q4 2024 | +11.5% | +5.7% | -5.6% | |
| Q3 2024 | -9.0% | -10.4% | -28.0% | |
| Q2 2024 | +10.7% | +26.2% | +25.0% | |
| Q1 2024 | -4.5% | -5.8% | -30.3% | |
| Q4 2023 | -11.5% | -19.8% | -28.2% | |
| Q3 2023 | -19.5% | -11.1% | -15.4% | |
| Q2 2023 | +12.9% | +22.4% | -12.9% | |
| Q1 2023 | -12.3% | -17.7% | +4.1% | |
| Q4 2022 | +1.2% | -9.6% | +62.9% | |
| Q3 2022 | +0.5% | — | — | |
| Q2 2022 | -3.6% | — | — | |
| Q1 2022 | -1.3% | — | — | |
| Q4 2021 | -2.5% | — | — | |
| Q3 2021 | +3.4% | — | — | |
| Q2 2021 | -8.8% | — | — | |
| Q1 2021 | +5.4% | — | — | |
| Q4 2020 | +5.6% | — | — | |
| Q3 2020 | +3.9% | — | — | |
| Q2 2020 | +7.0% | — | — | |
| Q1 2020 | +1.6% | — | — | |
| Q4 2019 | -29.2% | — | — | |
| Q3 2019 | +0.9% | — | — | |
| Q2 2019 | +1.7% | — | — | |
| Q1 2019 | -2.9% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | -7.0% | — | — | |
| Q2 2018 | +2.1% | — | — | |
| Q1 2018 | +17.1% | — | — | |
| Q4 2017 | +19.0% | — | — | |
| Q3 2017 | +2.8% | — | — | |
| Q2 2017 | -12.4% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +13.7% | — | — | |
| Q3 2016 | -4.2% | — | — | |
| Q2 2016 | +32.8% | — | — | |
| Q1 2016 | +6.1% | — | — | |
| Q4 2015 | -8.6% | — | — | |
| Q3 2015 | -0.7% | — | — | |
| Q2 2015 | +15.2% | — | — | |
| Q1 2015 | +17.9% | — | — | |
| Q4 2014 | -2.4% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro